MX2019014988A - Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. - Google Patents

Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.

Info

Publication number
MX2019014988A
MX2019014988A MX2019014988A MX2019014988A MX2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A
Authority
MX
Mexico
Prior art keywords
reducing
patients
type
diabetes mellitus
cardiovascular events
Prior art date
Application number
MX2019014988A
Other languages
English (en)
Spanish (es)
Inventor
Norman R Rosenthal
Douglas K Ways
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019014988A publication Critical patent/MX2019014988A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019014988A 2017-06-12 2018-06-11 Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. MX2019014988A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2019014988A true MX2019014988A (es) 2020-08-06

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014988A MX2019014988A (es) 2017-06-12 2018-06-11 Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.

Country Status (15)

Country Link
US (2) US20180353470A1 (cg-RX-API-DMAC7.html)
EP (1) EP3638250A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020523408A (cg-RX-API-DMAC7.html)
KR (1) KR20200014406A (cg-RX-API-DMAC7.html)
CN (1) CN110740735A (cg-RX-API-DMAC7.html)
AU (1) AU2018283781B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019026120A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066874A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013940A2 (cg-RX-API-DMAC7.html)
EA (1) EA202090028A1 (cg-RX-API-DMAC7.html)
IL (1) IL271100A (cg-RX-API-DMAC7.html)
MX (1) MX2019014988A (cg-RX-API-DMAC7.html)
TW (1) TWI835735B (cg-RX-API-DMAC7.html)
UA (1) UA127987C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018229630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NO2385374T3 (cg-RX-API-DMAC7.html) * 2010-05-05 2014-06-07
EP2568971B1 (en) * 2010-05-11 2020-10-14 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
AU2018283781A1 (en) 2019-12-19
US20210000792A1 (en) 2021-01-07
TWI835735B (zh) 2024-03-21
CO2019013940A2 (es) 2020-01-17
BR112019026120A2 (pt) 2020-07-07
AU2018283781B2 (en) 2023-09-28
KR20200014406A (ko) 2020-02-10
US20180353470A1 (en) 2018-12-13
IL271100A (en) 2020-01-30
CN110740735A (zh) 2020-01-31
JP2023113644A (ja) 2023-08-16
WO2018229630A1 (en) 2018-12-20
UA127987C2 (uk) 2024-03-06
JP2020523408A (ja) 2020-08-06
TW201904584A (zh) 2019-02-01
EP3638250A1 (en) 2020-04-22
EA202090028A1 (ru) 2020-04-03
CA3066874A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2021002321A (es) Nuevos metodos.
MX378422B (es) Uso de empagliflozina para el tratamiento de trastornos metabòlicos, la prevenciòn, y para la reducciòn del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX2018011088A (es) Composicion farmaceutica que comprende empagliflozina y sus usos.
EP4417255A3 (en) Compositions and methods for treating pulmonary hypertension
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2019000677A (es) Células miméticas de células b.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
MX2019014988A (es) Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.
BR112017015840A2 (pt) método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2016012127A (es) Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.
WO2014187964A3 (en) Novel treatment of metabolic diseases